Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best AI driven biotech stocks to invest in.

As of the June 5 close, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) had a strongly bullish consensus sentiment. Based on a 1-year target price of $88.14, the stock offers an upside potential of more than 167%% at the prevailing level. It received Buy ratings from all 8 analysts who provided coverage.

Copyright: nexusplexus / 123RF Stock Photo

On June 2, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) revealed that the company will be sharing data across 6 different presentations during the Endocrine Society’s Annual Meeting, ENDO 2026, in mid-June. Three of those presentations will be around PALSONIFY, which will incorporate data on long-term safety and efficacy from the open-label extension (OLE) studies, i.e., PATHFNDR-1 and PATHFNDR-2.

Besides that, there will be three presentations around the company’s atumelnant clinical development program. The company will share data from the Phase 2 study on congenital adrenal hyperplasia (CAH), along with Phase 1b/2a results for ACTH-dependent Cushing’s syndrome.

Back on May 15, Gavin Clark-Gartner from Evercore ISI reduced his target price for Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) from $89 to $88, resulting in an adjusted upside potential in excess of 167%. The firm maintained its Outperform rating on the stock.

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.